Metronidazol Noridem (Metronidazole)

Metronidazole penetrates susceptible anaerobic microbes and protozoa, where enzymatic reduction of its nitro group creates reactive radicals. These radicals damage microbial DNA and inhibit nucleic acid synthesis, leading to cell death while sparing most aerobic human cells.

The dosage of Metronidazol Noridem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals set the appropriate dose and infusion rate for each individual case.

The safety of Metronidazol Noridem in pregnancy has not been definitively established, and it is classified as a Category unknown. It should be used only when the potential benefits justify any potential risk to the fetus. Breastfeeding mothers should consult their physician, as metronidazole can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metronidazol Noridem shares the same class mechanism as other nitroimidazoles such as tinidazole, but it is formulated for intravenous administration, offering rapid systemic exposure suitable for severe infections. Oral nitroimidazoles are used for milder cases, whereas the IV form ensures higher plasma concentrations for critical care settings.

Metronidazol Noridem should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the product. Before use, inspect the vial for particulate matter and ensure aseptic technique during preparation.

The product is supplied as a sterile solution for intravenous injection. It is administered by a healthcare professional via a controlled infusion, typically diluted in compatible IV fluids according to the prescribing information and patient-specific dosing instructions.

Serious risks include seizures, peripheral neuropathy, and severe allergic reactions such as anaphylaxis. Patients should be monitored for neurologic symptoms, skin rash, or breathing difficulties, and treatment should be discontinued immediately if any of these events occur.

Metronidazol Noridem is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients who have consumed alcohol within 24 hours due to the risk of a disulfiram‑like reaction.